The role of HMGB1 in the pathogenesis of rheumatic disease

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 1-2, 2010, Pages 141-148

  Andersson, Ulf ^a   Harris, Helena Erlandsson ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; HMGB1; Inflammation; Necrosis; Rheumatic diseases; Therapy

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; GHRELIN; GOLD SALT; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN MONOCLONAL ANTIBODY; INFLIXIMAB; MEMBRANE PROTEIN; MESSENGER RNA; OXALIPLATIN; PROTEIN ANTIBODY; RAGE PROTEIN; THROMBOMODULIN; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICULAR CARTILAGE; BONE; CHOLINERGIC ACTIVITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; HUMAN; INFLAMMATION; MYOSITIS; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATIC DISEASE; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; EXTRACELLULAR SPACE; HMGB1 PROTEIN; HUMANS; INFLAMMATION; RHEUMATIC DISEASES;

EID: 74849136922     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2009.11.003     Document Type: Review

References (92)

1. Goodwin G.H., and Johns E.W. The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins. Methods Cell Biol. 16 (1977) 257-267
2. Bustin M., Lehn D.A., and Landsman D. Structural features of the HMG chromosomal proteins and their genes. Biochim. Biophys. Acta 1049 (1990) 231-243
3. Bonaldi T., Langst G., Strohner R., Becker P.B., and Bianchi M.E. The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. EMBO J. 21 (2002) 6865-6873
4. Travers A.A. Priming the nucleosome: a role for HMGB proteins?. EMBO Rep. 4 (2003) 131-136
5. Bustin M., and Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog. Nucleic Acid Res. Mol. Biol. 54 (1996) 35-100
6. Ferrari S., Ronfani L., Calogero S., and Bianchi M.E. The mouse gene coding for high mobility group 1 protein (HMG1). J. Biol. Chem. 269 (1994) 28803-28808
7. Qin S., Wang H., Yuan R., Li H., Ochani M., Ochani K., Rosas-Ballina M., Czura C.J., Huston J.M., Miller E., Lin X., Sherry B., Kumar A., Larosa G., Newman W., Tracey K.J., and Yang H. Role of HMGB1 in apoptosis-mediated sepsis lethality. J. Exp. Med. 203 (2006) 1637-1642
8. Liu K., Mori S., Takahashi H.K., Tomono Y., Wake H., Kanke T., Sato Y., Hiraga N., Adachi N., Yoshino T., and Nishibori M. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J. 21 (2007) 3904-3916
9. Chen G.Y., Tang J., Zheng P., and Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323 (2009) 1722-1725
10. Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., Susarla S.M., Ulloa L., Wang H., DiRaimo R., Czura C.J., Roth J., Warren H.S., Fink M.P., Fenton M.J., Andersson U., and Tracey K.J. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 296-301
11. Kokkola R., Li J., Sundberg E., Aveberger A.-C., Palmblad K., Yang H., Tracey K., Andersson U., and Erlandsson Harris H. Successful therapy in collagen-induced arthritis in mice and rats targeting extracellular HMGB1 activity. Arthritis Rheum. 48 (2003) 2052-2058
12. Hamada T., Torikai M., Kuwazuru A., Tanaka M., Horai N., Fukuda T., Yamada S., Nagayama S., Hashiguchi K., Sunahara N., Fukuzaki K., Nagata R., Komiya S., Maruyama I., Fukuda T., and Abeyama K. Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum. 58 (2008) 2675-2685
13. Suda K., Kitagawa Y., Ozawa S., Saikawa Y., Ueda M., Ebina M., Yamada S., Hashimoto S., Fukata S., Abraham E., Maruyama I., Kitajima M., and Ishizaka A. Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J. Surg. 30 (2006) 1755-1762
14. Levy R.M., Mollen K.P., Prince J.M., Kaczorowski D.J., Vallabhaneni R., Liu S., Tracey K.J., Lotze M.T., Hackam D.J., Fink M.P., Vodovotz Y., and Billiar T.R. Systemic inflammation and remote organ injury following trauma require HMGB1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293 (2007) R1538-R1544
15. Abeyama K., Stern D.M., Ito Y., Kawahara K., Yoshimoto Y., Tanaka M., Uchimura T., Ida N., Yamazaki Y., Yamada S., Yamamoto Y., Yamamoto H., Iino S., Taniguchi N., and Maruyama I. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 115 (2005) 1267-1274
16. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., and Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248-251
17. Muhammad S., Barakat W., Stoyanov S., Murikinati S., Yang H., Tracey K.J., Bendszus M., Rossetti G., Nawroth P.P., Bierhaus A., and Schwaninger M. The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci. 28 (2008) 12023-12031
18. Tsung A., Sahai R., Tanaka H., Nakao A., Fink M.P., Lotze M.T., Yang H., Li J., Tracey K.J., Geller D.A., and Billiar T.R. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201 (2005) 1135-1143
19. Andrassy M., Volz H.C., Igwe J.C., Funke B., Eichberger S.N., Kaya Z., Buss S., Autschbach F., Pleger S.T., Lukic I.K., Bea F., Hardt S.E., Humpert P.M., Bianchi M.E., Mairbaurl H., Nawroth P.P., Remppis A., Katus H.A., and Bierhaus A. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117 (2008) 3216-3226
20. Sawa H., Ueda T., Takeyama Y., Yasuda T., Shinzeki M., Nakajima T., and Kuroda Y. Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis. World J. Gastroenterol. 12 (2006) 7666-7670
21. Yuan H., Jin X., Sun J., Li F., Feng Q., Zhang C., Cao Y., and Wang Y. Protective effect of HMGB1 a box on organ injury of acute pancreatitis in mice. Pancreas 38 (2009) 143-148
22. Abraham E., Arcaroli J., Carmody A., Wang H., and Tracey K.J. HMG-1 as a mediator of acute lung inflammation. J. Immunol. 165 (2000) 2950-2954
23. Ueno H., Matsuda T., Hashimoto S., Amaya F., Kitamura Y., Tanaka M., Kobayashi A., Maruyama I., Yamada S., Hasegawa N., Soejima J., Koh H., and Ishizaka A. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am. J. Respir. Crit. Care Med. 170 (2004) 1310-1316
24. Kim J.Y., Park J.S., Strassheim D., Douglas I., Diaz del Valle F., Asehnoune K., Mitra S., Kwak S.H., Yamada S., Maruyama I., Ishizaka A., and Abraham E. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am. J. Physiol. Lung Cell. Mol. Physiol. 288 (2005) L958-L965
25. Ogawa E.N., Ishizaka A., Tasaka S., Koh H., Ueno H., Amaya F., Ebina M., Yamada S., Funakoshi Y., Soejima J., Moriyama K., Kotani T., Hashimoto S., Morisaki H., Abraham E., and Takeda J. Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. Am. J. Respir. Crit. Care Med. 174 (2006) 400-407
26. Gong Q., Xu J.F., Yin H., Liu S.F., Duan L.H., and Bian Z.L. Protective effect of antagonist of high-mobility group box 1 on lipopolysaccharide-induced acute lung injury in mice. Scand. J. Immunol. 69 (2009) 29-35
27. Andersson U., Wang H., Palmblad K., Aveberger A.-C., Bloom O., Erlandsson-Harris H., Janson A., Kokkola R., Yang H., and Tracey K.J. HMG-1 stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192 (2000) 565-570
28. Bianchi M.E. HMGB1 loves company. J. Leukoc. Biol. 86 (2009) 573-576
29. Bonaldi T., Talamo F., Scaffidi P., Ferrera D., Porto A., Bachi A., Rubartelli A., Agresti A., and Bianchi M.E. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22 (2003) 5551-5560
30. Youn J.H., and Shin J.S. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J. Immunol. 177 (2006) 7889-7897
31. Ito I., Fukazawa J., and Yoshida M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J. Biol. Chem. 282 (2007) 16336-16344
32. Kazama H., Ricci J.E., Herndon J.M., Hoppe G., Green D.R., and Ferguson T.A. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29 (2008) 21-32
33. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., Nagashima M., Lundh E.R., Vijay S., Nitecki D., Morser J., Stern D., and Schmidt A.M. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270 (1995) 25752-25761
34. Park J.S., Gamboni-Robertson F., He Q., Svetkauskaite D., Kim J.Y., Strassheim D., Sohn J.W., Yamada S., Maruyama I., Banerjee A., Ishizaka A., and Abraham E. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell. Physiol. 290 (2006) C917-C924
35. Ivanov S., Dragoi A.M., Wang X., Dallacosta C., Louten J., Musco G., Sitia G., Yap G.S., Wan Y., Biron C.A., Bianchi M.E., Wang H., and Chu W.M. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110 (2007) 1970-1981
36. Degryse B., Bonaldi T., Scaffidi P., Muller S., Resnati M., Sanvito F., Arrigoni G., and Bianchi M.E. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J. Cell. Biol. 152 (2001) 1197-1206
37. Huttunen H.J., Fages C., Kuja-Panula J., Ridley A.J., and Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 62 (2002) 4805-4811
38. Li J., Kokkola R., Tabibzadeh S., Yang R., Ochani M., Qiang X., Harris H.E., Czura C.J., Wang H., Ulloa L., Warren H.S., Moldawer L.L., Fink M.P., Andersson U., Tracey K.J., and Yang H. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med. 9 (2003) 37-45
39. Yuan Z., Chen J., Zhang Y., and Peng Y. Construction and characterization of the HMGB1 mutant as a competitive antagonist to HMGB1 induced cytokines release. Biochem. Biophys. Res. Commun. 372 (2008) 703-707
40. Tian J., Avalos A.M., Mao S.Y., Chen B., Senthil K., Wu H., Parroche P., Drabic S., Golenbock D., Sirois C., Hua J., An L.L., Audoly L., La Rosa G., Bierhaus A., Naworth P., Marshak-Rothstein A., Crow M.K., Fitzgerald K.A., Latz E., Kiener P.A., and Coyle A.J. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8 (2007) 487-496
41. Scaffidi P., Misteli T., and Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418 (2002) 191-195
42. Youn J.H., Oh Y.J., Kim E.S., Choi J.E., and Shin J.S. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J. Immunol. 180 (2008) 5067-5074
43. Hreggvidsdottir H.S., Ostberg T., Wahamaa H., Schierbeck H., Aveberger A.C., Klevenvall L., Palmblad K., Ottosson L., Andersson U., and Harris H.E. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol. 86 (2009) 655-662
44. Campana L., Bosurgi L., Bianchi M.E., Manfredi A.A., and Rovere-Querini P. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J. Leukoc. Biol. 86 (2009) 609-615
45. Sha Y., Zmijewski J., Xu Z., and Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 180 (2008) 2531-2537
46. Urbonaviciute V., Furnrohr B.G., Meister S., Munoz L., Heyder P., De Marchis F., Bianchi M.E., Kirschning C., Wagner H., Manfredi A.A., Kalden J.R., Schett G., Rovere-Querini P., Herrmann M., and Voll R.E. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205 (2008) 3007-3018
47. van Zoelen M.A., Yang H., Florquin S., Meijers J.C., Akira S., Arnold B., Nawroth P.P., Bierhaus A., Tracey K.J., and van der Poll T. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 31 (2009) 280-284
48. Orlova V.V., Choi E.Y., Xie C., Chavakis E., Bierhaus A., Ihanus E., Ballantyne C.M., Gahmberg C.G., Bianchi M.E., Nawroth P.P., and Chavakis T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 26 (2007) 1129-1139
49. Ramasamy R., Yan S.F., and Schmidt A.M. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J. Leukoc. Biol. 86 (2009) 505-512
50. Yu M., Wang H., Ding A., Golenbock D.T., Latz E., Czura C.J., Fenton M.J., Tracey K.J., and Yang H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26 (2006) 174-179
51. van Beijnum J.R., Buurman W.A., and Griffioen A.W. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11 (2008) 91-99
52. Wähämaa H., Vallerskog T., Qin S., Lunderius C., Larosa G., Andersson U., and Harris H.E. HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay. J. Leukoc. Biol. 81 (2007) 129-136
53. Gardella S., Andrei C., Ferrera D., Lotti L.V., Torrisi M.R., Bianchi M.E., and Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 13 (2002) 995-1001
54. Jiang W., Bell C.W., and Pisetsky D.S. The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid. J. Immunol. 178 (2007) 6495-6503
55. Kawane K., Ohtani M., Miwa K., Kizawa T., Kanbara Y., Yoshioka Y., Yoshikawa H., and Nagata S. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 443 (2006) 998-1002
56. Kokkola R., Sundberg E., Ulfgren A.K., Palmblad K., Li J., Wang H., Ulloa L., Yang H., Yan X.J., Furie R., Chiorazzi N., Tracey K.J., Andersson U., and Harris H.E. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 46 (2002) 2598-2603
57. Taniguchi N., Kawahara K., Yone K., Hashiguchi T., Yamakuchi M., Goto M., Inoue K., Yamada S., Ijiri K., Matsunaga S., Nakajima T., Komiya S., and Maruyama I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 48 (2003) 971-981
58. Pullerits R., Jonsson I.-M., Verdrengh M., Bokarewa M., Andersson U., Erlandsson Harris H., and Tarkowski A. High mobility group chromosomal protein 1, a DNA-binding cytokine, induces arthritis. Arthritis Rheum. 48 (2003) 1693-1700
59. Östberg T., Wähämaa H., Palmblad K., Ito N., Stridh P., Shoshan M., Lotze M.T., Harris H.E., and Andersson U. Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Res. Ther. 10 (2008) R1
60. Goldstein R.S., Bruchfeld A., Yang L., Qureshi A.R., Gallowitsch-Puerta M., Patel N.B., Huston B.J., Chavan S., Rosas-Ballina M., Gregersen P.K., Czura C.J., Sloan R.P., Sama A.E., and Tracey K.J. Cholinergic anti-inflammatory pathway activity and high mobility group box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol. Med. 13 (2007) 210-215
61. Huang Q., Ma Y., Adebayo A., and Pope R.M. Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthritis Rheum. 56 (2007) 2192-2201
62. Palmblad K., Sundberg E., Diez M., Soderling R., Aveberger A.C., Andersson U., and Erlandsson Harris H. Morphological characterization of intra-articular HMGB1 expression during the course of collagen-induced arthritis. Arthritis Res. Ther. 9 (2007) R35
63. Parkkinen J., and Rauvala H. Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J. Biol. Chem. 266 (1991) 16730-16735
64. Yamoah K., Brebene A., Baliram R., Inagaki K., Dolios G., Arabi A., Majeed R., Amano H., Wang R., Yanagisawa R., and Abe E. High-mobility group box proteins modulate tumor necrosis factor-alpha expression in osteoclastogenesis via a novel deoxyribonucleic acid sequence. Mol. Endocrinol. 22 (2008) 1141-1153
65. Yang J., Shah R., Robling A.G., Templeton E., Yang H., Tracey K.J., and Bidwell J.P. HMGB1 is a bone-active cytokine. J. Cell. Physiol. 214 (2008) 730-739
66. Zhou Z., Han J.Y., Xi C.X., Xie J.X., Feng X., Wang C.Y., Mei L., and Xiong W.C. HMGB1 regulates RANKL-induced osteoclastogenesis in a manner dependent on RAGE. J. Bone Miner. Res. 23 (2008) 1084-1096
67. Mouri F., Tsukada J., Mizobe T., Higashi T., Yoshida Y., Minami Y., Izumi H., Kominato Y., Kohno K., and Tanaka Y. Intracellular HMGB1 transactivates the human IL1B gene promoter through association with an Ets transcription factor PU.1. Eur. J. Haematol. 80 (2008) 10-19
68. af Klint E., Grundtman C., Engstrom M., Catrina A.I., Makrygiannakis D., Klareskog L., Andersson U., and Ulfgren A.K. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum. 52 (2005) 3880-3889
69. Ulfgren A.K., Grundtman C., Borg K., Alexanderson H., Andersson U., Harris H.E., and Lundberg I.E. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum. 50 (2004) 1586-1594
70. Zetterström C.K., Jiang W., Wähämaa H., Östberg T., Aveberger A.C., Schierbeck H., Lotze M.T., Andersson U., Pisetsky D.S., and Harris H.E. Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. J. Leukoc. Biol. 83 (2008) 31-38
71. Sundberg E., Grundtman C., Af Klint E., Lindberg J., Ernestam S., Ulfgren A.K., Harris H.E., and Andersson U. Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients-a prospective clinical study. Arthritis Res. Ther. 10 (2008) R33
72. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., Kambham N., Bierhaus A., Nawroth P., Neurath M.F., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Stern D., and Schmidt A.M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 (1999) 889-901
73. Van de Wouwer M., Plaisance S., De Vriese A., Waelkens E., Collen D., Persson J., Daha M.R., and Conway E.M. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J. Thromb. Haemost. 4 (2006) 1813-1824
74. Bierhaus A., Humpert P.M., Morcos M., Wendt T., Chavakis T., Arnold B., Stern D.M., Nawroth P.P., and Understanding R. the receptor for advanced glycation end products. J. Mol. Med. 83 (2005) 876-886
75. Geroldi D., Falcone C., and Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13 (2006) 1971-1978
76. Hofmann M.A., Drury S., Hudson B.I., Gleason M.R., Qu W., Lu Y., Lalla E., Chitnis S., Monteiro J., Stickland M.H., Bucciarelli L.G., Moser B., Moxley G., Itescu S., Grant P.J., Gregersen P.K., Stern D.M., and Schmidt A.M. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 3 (2002) 123-135
77. van Maanen M.A., Lebre M.C., van der Poll T., LaRosa G.J., Elbaum D., Vervoordeldonk M.J., and Tak P.P. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum. 60 (2009) 114-122
78. Chorny A., Anderson P., Gonzalez-Rey E., and Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J. Immunol. 180 (2008) 8369-8377
79. Barkauskaite V., Ek M., Popovic K., Harris H.E., Wahren-Herlenius M., and Nyberg F. Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus 16 (2007) 794-802
80. Hayashi A., Nagafuchi H., Ito I., Hirota K., Yoshida M., and Ozaki S. Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod. Rheumatol. 19 (2009) 283-292
81. Jiang W., and Pisetsky D.S. Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Ann. Rheum. Dis. 67 (2008) 727-728
82. Mistry A.R., Falciola L., Monaco L., Tagliabue R., Acerbis G., Knight A., Harbottle R.P., Soria M., Bianchi M.E., Coutelle C., and Hart S.L. Recombinant HMG1 protein produced in Pichia pastoris: a nonviral gene delivery agent. Biotechniques 22 (1997) 718-729
83. Shen Y., Peng H., Deng J., Wen Y., Luo X., Pan S., Wu C., and Feng M. High mobility group box 1 protein enhances polyethylenimine mediated gene delivery in vitro. Int. J. Pharm. 375 (2009) 140-147
84. Han J.S., Kim K., and Lee M. A high mobility group B-1 box A peptide combined with an artery wall binding peptide targets delivery of nucleic acids to smooth muscle cells. J. Cell. Biochem. 107 (2009) 163-170
85. De Mori R., Straino S., Di Carlo A., Mangoni A., Pompilio G., Palumbo R., Bianchi M.E., Capogrossi M.C., and Germani A. Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2377-2383
86. Tzeng H.P., Fan J., Vallejo J.G., Dong J.W., Chen X., Houser S.R., and Mann D.L. Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H1490-H1496
87. Grundtman C., Bruton J., Yamada T., Östberg T., Pisetsky D.S., Erlandsson Harris H., Andersson U., Lundberg I.E., and Westerblad H. The functional activities of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J. (2009) (Electronic publication ahead of print)
88. Uesugi H., Ozaki S., Sobajima J., Osakada F., Shirakawa H., Yoshida M., and Nakao K. Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases. J. Rheumatol. 25 (1998) 703-709
89. Neuer G., Bustin M., Michels H., Truckenbrodt H., and Bautz F.A. Autoantibodies to the chromosomal protein HMG-17 in juvenile rheumatoid arthritis. Arthritis Rheum. 35 (1992) 472-475
90. Wittemann B., Neuer G., Michels H., Truckenbrodt H., and Bautz F.A. Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum. 33 (1990) 1378-1383
91. Burlingame R.W., Rubin R.L., and Rosenberg A.M. Autoantibodies to chromatin components in juvenile rheumatoid arthritis. Arthritis Rheum. 36 (1993) 836-841
92. Pan P., Cardinal J., Dhupar R., Rosengart M.R., Lotze M.T., Geller D.A., Billiar T.R., and Tsung A. Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality. J. Leukoc. Biol. 86 (2009) 625-632